Our data showed, for the first time in the literature, the effects of different PE protocols on cardio-metabolic parameters, QoL, and PA in a BCS population not treated with CHT or HER-2 inhibitors, with data about CV and BC outcomes, PA, CV-QoL, and HR-QoL at a 34-month follow-up. Here, ERBB2 is linked to breast cancer.